Rein Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for neurological and inflammatory conditions, with no reported revenue or income, operating on Nasdaq, and valued at approximately $54 million as of mid-2024.

# Rein Therapeutics, Inc. Company Summary

**Overview:**  
Rein Therapeutics, Inc. is a biopharmaceutical company focused on the development of innovative therapies, with a particular emphasis on compounds related to neuroscience, inflammation, and other complex disease areas. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the ticker symbol **RNTX**.

---

## Business Focus and Activities
- The company engages in the research and development of biopharmaceuticals, with a strategic focus on therapeutic compounds that may target neurological and inflammatory conditions.
- It has historically been involved in licensing agreements, licensing patents, and conducting clinical and preclinical research.

## Financial Information
- **Number of Customers:** Not specified in the filing.
- **Employees:** Not specified in the filing.
- **Revenue:** Not reported; no specific revenue figures provided.
- **Net Income:** Not reported; the filing does not include income or loss statements or net income figures.

## Corporate Details
- **Principal Offices:** Austin, Texas (12407 N. Mopac Expy, Suite 250 #390, ZIP Code 78758).
- **Telephone:** (737) 802-1989.
- **Market Capitalization (as of June 28, 2024):** Approximately $54 million, based on reported market value of common equity held by non-affiliates.
- **Shares Outstanding:** 21,992,387 shares of common stock as of March 27, 2025.
- **Stock Listing:** Nasdaq Capital Market.

## Notable Developments
- The company completed an acquisition of Lung Therapeutics, Inc. in October 2023.
- The company has engaged in private placements and warrant exchanges, involving significant financing and issuance of preferred stock and warrants to investors linked with Bios Partners.
- The company maintains a focus on internal governance, including committees for audit, compensation, and governance, and adheres to Nasdaq standards for independence and disclosures.

---

## Summary
Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company without reported revenue or income in the provided document. It is focused on developing therapies targeting complex diseases, operates with a corporate structure compliant with Nasdaq requirements, and has a market valuation around $54 million as of mid-2024. Specific operational metrics such as customer counts or detailed financial performance are not disclosed in this filing.

Aileron Therapeutics, Inc. is a biotechnology company focusing on innovative therapies for oncology and serious illnesses through its Stapled Peptide Platform.

# Aileron Therapeutics, Inc. Overview

**Business Focus:**
Aileron Therapeutics, Inc. is a biotechnology company that specializes in designing and developing innovative therapies that utilize a unique platform technology called the **Stapled Peptide Platform**. This platform aims to address challenges in drug development for diseases that have high unmet medical needs, particularly in cancer and other serious illnesses.

### Key Details

- **Founded:** The company was incorporated in 2009.
- **Headquarters:** Aileron is located in Austin, Texas.

### Technology Platform

1. **Stapled Peptides:** Aileron's main technological innovation involves creating stapled peptides, which are engineered versions of natural peptides designed to improve their stability and ability to penetrate cells. This technology aims to make previously untreatable targets more accessible for therapeutic intervention.
  
2. **Therapeutic Areas:** The company primarily focuses on the development of treatments for oncology and other conditions requiring targeted therapeutic modalities.

### Company Structure

- **Employees:** As of April 2024, Aileron Therapeutics employs around **30 to 50 employees** (exact number not specified in the provided data).
  
- **Board of Directors:** The board consists of seven members with considerable experience in biotechnology and business management.

### Customers and Market

- **Customers:** Aileron primarily targets healthcare providers and institutions, focusing on developing treatments that will benefit patients in need of innovative therapeutic options. Its indirect customers include patients who benefit from its therapies.
  
- **Collaboration and Partnerships:** The company often collaborates with pharmaceutical firms and research institutions to advance its drug development efforts.

### Financials

- **Revenue:** Aileron is in the clinical development phase and does not have consistent revenue streaming from product sales as of the last reporting in April 2024. Any revenue generated would likely stem from research collaborations and potential licensing agreements.
  
- **Income:** The company reports operating losses that are typical of biotech firms in the development stage, significantly dependent on funding from capital raises, partnerships, and grants.

### Recent Developments

- **Lung Acquisition:** In October 2023, Aileron acquired Lung Therapeutics, Inc., which expanded its pipeline and introduced new technologies and therapies into its portfolio.
  
- **Current Status in Development:** The firm is working on advancing its therapeutic products through clinical trials as part of its growth strategy.

### Conclusion

Aileron Therapeutics, Inc. is at the forefront of peptide-based drug development, looking to transform the therapeutic landscape for oncology and serious illnesses. While it currently operates at a loss typical of early-stage biotech companies, its innovative technology and recent acquisition position it for potential growth and market impact. 

**Note:** The specific details regarding the financial performance metrics like revenue, specific customer base numbers, or operational profit/loss weren't provided, reflecting the stage of development and the nature of the biotechnology sector. As they progress through clinical trials and partnerships, this data can be expected to evolve.

Rein Therapeutics, Inc.

10-K / April 30, 2025

10-K / April 29, 2024

10-K / April 30, 2025

Rein Therapeutics, Inc. Company Summary

Business Focus and Activities

Financial Information

Corporate Details

Notable Developments

Summary